Colorectal	B:C0009402
Choriocarcinoma	I:C0009402
in	O
a	O
Patient	O
with	O
Probable	O
Lynch	O
Syndrome	I:C2931459
Personalized	O
therapy	O
of	O
colorectal	O
cancer	I:C1527249
is	O
influenced	O
by	O
morphological	O
,	O
molecular	O
,	O
and	O
host	O
-	O
related	O
factors	O
.	O

Colorectal	O
Choriocarcinoma	I:C0009402
in	O
a	O
Patient	O
with	O
Probable	O
Lynch	B:C2931459
Syndrome	I:C2931459
Personalized	O
therapy	O
of	O
colorectal	O
cancer	I:C1527249
is	O
influenced	O
by	O
morphological	O
,	O
molecular	O
,	O
and	O
host	O
-	O
related	O
factors	O
.	O

Colorectal	O
Choriocarcinoma	I:C0009402
in	O
a	O
Patient	O
with	O
Probable	O
Lynch	O
Syndrome	I:C2931459
Personalized	O
therapy	B:C0087111
of	O
colorectal	O
cancer	I:C1527249
is	O
influenced	O
by	O
morphological	O
,	O
molecular	O
,	O
and	O
host	O
-	O
related	O
factors	O
.	O

Colorectal	O
Choriocarcinoma	I:C0009402
in	O
a	O
Patient	O
with	O
Probable	O
Lynch	O
Syndrome	I:C2931459
Personalized	O
therapy	O
of	O
colorectal	B:C1527249
cancer	I:C1527249
is	O
influenced	O
by	O
morphological	O
,	O
molecular	O
,	O
and	O
host	O
-	O
related	O
factors	O
.	O

Here	O
,	O
we	O
report	O
the	O
comprehensive	O
clinicopathological	O
and	O
molecular	B:C1513380
analysis	I:C1513380
of	O
an	O
extra-gestational	O
colorectal	O
choriocarcinoma	I:C0009402
in	O
a	O
patient	O
with	O
probable	O
Lynch	O
syndrome	I:C2931459
.	O

Here	O
,	O
we	O
report	O
the	O
comprehensive	O
clinicopathological	O
and	O
molecular	O
analysis	I:C1513380
of	O
an	O
extra-gestational	B:C0032961
colorectal	O
choriocarcinoma	I:C0009402
in	O
a	O
patient	O
with	O
probable	O
Lynch	O
syndrome	I:C2931459
.	O

Here	O
,	O
we	O
report	O
the	O
comprehensive	O
clinicopathological	O
and	O
molecular	O
analysis	I:C1513380
of	O
an	O
extra-gestational	O
colorectal	B:C0009402
choriocarcinoma	I:C0009402
in	O
a	O
patient	O
with	O
probable	O
Lynch	O
syndrome	I:C2931459
.	O

Here	O
,	O
we	O
report	O
the	O
comprehensive	O
clinicopathological	O
and	O
molecular	O
analysis	I:C1513380
of	O
an	O
extra-gestational	O
colorectal	O
choriocarcinoma	I:C0009402
in	O
a	O
patient	O
with	O
probable	O
Lynch	B:C2931459
syndrome	I:C2931459
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
with	O
history	B:C0262926
of	I:C0262926
gastric	O
cancer	I:C0024623
at	O
age	O
36	O
presented	O
with	O
a	O
transmurally	O
invasive	O
tumor	I:C0677898
of	O
the	O
right	O
hemicolon	I:C1305188
and	O
liver	O
metastasis	I:C0494165
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
with	O
history	O
of	I:C0262926
gastric	B:C0024623
cancer	I:C0024623
at	O
age	O
36	O
presented	O
with	O
a	O
transmurally	O
invasive	O
tumor	I:C0677898
of	O
the	O
right	O
hemicolon	I:C1305188
and	O
liver	O
metastasis	I:C0494165
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
with	O
history	O
of	I:C0262926
gastric	O
cancer	I:C0024623
at	O
age	O
36	O
presented	O
with	O
a	O
transmurally	O
invasive	B:C0677898
tumor	I:C0677898
of	O
the	O
right	O
hemicolon	I:C1305188
and	O
liver	O
metastasis	I:C0494165
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
with	O
history	O
of	I:C0262926
gastric	O
cancer	I:C0024623
at	O
age	O
36	O
presented	O
with	O
a	O
transmurally	O
invasive	O
tumor	I:C0677898
of	O
the	O
right	B:C1305188
hemicolon	I:C1305188
and	O
liver	O
metastasis	I:C0494165
.	O

A	O
61	O
-	O
year	O
-	O
old	O
female	O
with	O
history	O
of	I:C0262926
gastric	O
cancer	I:C0024623
at	O
age	O
36	O
presented	O
with	O
a	O
transmurally	O
invasive	O
tumor	I:C0677898
of	O
the	O
right	O
hemicolon	I:C1305188
and	O
liver	B:C0494165
metastasis	I:C0494165
.	O

A	O
right	B:C0192861
hemicolectomy	I:C0192861
was	O
performed	O
.	O

Histopathological	O
analysis	O
showed	O
a	O
mixed	B:C0041182
trophoblastic	I:C0041182
and	O
syncytiotrophoblastic	O
differentiation	O
,	O
consistent	O
with	O
choriocarcinoma	O
.	O

Histopathological	O
analysis	O
showed	O
a	O
mixed	O
trophoblastic	I:C0041182
and	O
syncytiotrophoblastic	B:C1135936
differentiation	O
,	O
consistent	O
with	O
choriocarcinoma	O
.	O

Histopathological	O
analysis	O
showed	O
a	O
mixed	O
trophoblastic	I:C0041182
and	O
syncytiotrophoblastic	O
differentiation	O
,	O
consistent	O
with	O
choriocarcinoma	B:C0008497
.	O

Disease	B:C0242656
progression	I:C0242656
was	O
rapid	O
under	O
oxaliplatin	O
,	O
capecitabine	O
,	O
irinotecan	O
,	O
and	O
bevacizumab	O
.	O

Disease	O
progression	I:C0242656
was	O
rapid	O
under	O
oxaliplatin	B:C0069717
,	O
capecitabine	O
,	O
irinotecan	O
,	O
and	O
bevacizumab	O
.	O

Disease	O
progression	I:C0242656
was	O
rapid	O
under	O
oxaliplatin	O
,	O
capecitabine	B:C0671970
,	O
irinotecan	O
,	O
and	O
bevacizumab	O
.	O

Disease	O
progression	I:C0242656
was	O
rapid	O
under	O
oxaliplatin	O
,	O
capecitabine	O
,	O
irinotecan	B:C0123931
,	O
and	O
bevacizumab	O
.	O

Disease	O
progression	I:C0242656
was	O
rapid	O
under	O
oxaliplatin	O
,	O
capecitabine	O
,	O
irinotecan	O
,	O
and	O
bevacizumab	B:C0796392
.	O

Molecular	B:C1285572
phenotyping	I:C1285572
identified	O
loss	O
of	O
mismatch	O
-	I:C1333235
repair	I:C1333235
protein	I:C1333235
immunostaining	O
for	O
PMS2	O
,	O
microsatellite	O
instability	I:C0920269
,	O
a	O
lack	O
of	O
MLH1	O
promoter	O
methylation	O
,	O
and	O
lack	O
of	O
BRAF	O
mutation	I:C1511021
suggestive	O
of	O
Lynch	O
syndrome	I:C2931459
.	O

Molecular	O
phenotyping	I:C1285572
identified	O
loss	O
of	O
mismatch	B:C1333235
-	I:C1333235
repair	I:C1333235
protein	I:C1333235
immunostaining	O
for	O
PMS2	O
,	O
microsatellite	O
instability	I:C0920269
,	O
a	O
lack	O
of	O
MLH1	O
promoter	O
methylation	O
,	O
and	O
lack	O
of	O
BRAF	O
mutation	I:C1511021
suggestive	O
of	O
Lynch	O
syndrome	I:C2931459
.	O

Molecular	O
phenotyping	I:C1285572
identified	O
loss	O
of	O
mismatch	O
-	I:C1333235
repair	I:C1333235
protein	I:C1333235
immunostaining	B:C0487602
for	O
PMS2	O
,	O
microsatellite	O
instability	I:C0920269
,	O
a	O
lack	O
of	O
MLH1	O
promoter	O
methylation	O
,	O
and	O
lack	O
of	O
BRAF	O
mutation	I:C1511021
suggestive	O
of	O
Lynch	O
syndrome	I:C2931459
.	O

Molecular	O
phenotyping	I:C1285572
identified	O
loss	O
of	O
mismatch	O
-	I:C1333235
repair	I:C1333235
protein	I:C1333235
immunostaining	O
for	O
PMS2	B:C1333235
,	O
microsatellite	O
instability	I:C0920269
,	O
a	O
lack	O
of	O
MLH1	O
promoter	O
methylation	O
,	O
and	O
lack	O
of	O
BRAF	O
mutation	I:C1511021
suggestive	O
of	O
Lynch	O
syndrome	I:C2931459
.	O

Molecular	O
phenotyping	I:C1285572
identified	O
loss	O
of	O
mismatch	O
-	I:C1333235
repair	I:C1333235
protein	I:C1333235
immunostaining	O
for	O
PMS2	O
,	O
microsatellite	B:C0920269
instability	I:C0920269
,	O
a	O
lack	O
of	O
MLH1	O
promoter	O
methylation	O
,	O
and	O
lack	O
of	O
BRAF	O
mutation	I:C1511021
suggestive	O
of	O
Lynch	O
syndrome	I:C2931459
.	O

Molecular	O
phenotyping	I:C1285572
identified	O
loss	O
of	O
mismatch	O
-	I:C1333235
repair	I:C1333235
protein	I:C1333235
immunostaining	O
for	O
PMS2	O
,	O
microsatellite	O
instability	I:C0920269
,	O
a	O
lack	O
of	O
MLH1	O
promoter	O
methylation	O
,	O
and	O
lack	O
of	O
BRAF	B:C1511021
mutation	I:C1511021
suggestive	O
of	O
Lynch	O
syndrome	I:C2931459
.	O

Molecular	O
phenotyping	I:C1285572
identified	O
loss	O
of	O
mismatch	O
-	I:C1333235
repair	I:C1333235
protein	I:C1333235
immunostaining	O
for	O
PMS2	O
,	O
microsatellite	O
instability	I:C0920269
,	O
a	O
lack	O
of	O
MLH1	O
promoter	O
methylation	O
,	O
and	O
lack	O
of	O
BRAF	O
mutation	I:C1511021
suggestive	O
of	O
Lynch	B:C2931459
syndrome	I:C2931459
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
revealed	O
an	O
ataxia	B:C3711796
telangiectasia	I:C3711796
mutated	I:C3711796
(	I:C3711796
p.	I:C3711796
P604S	I:C3711796
)	I:C3711796
missense	O
mutation	I:C0599155
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
revealed	O
an	O
ataxia	O
telangiectasia	I:C3711796
mutated	I:C3711796
(	I:C3711796
p.	I:C3711796
P604S	I:C3711796
)	I:C3711796
missense	B:C0599155
mutation	I:C0599155
.	O

A	O
bleomycin	B:C0005740
,	O
etoposide	O
,	O
and	O
cisplatin	O
treatment	O
protocol	I:C0040808
targeting	O
germ	O
cell	I:C4021985
neoplasia	I:C4021985
lead	O
to	O
disease	O
remission	I:C0544452
and	O
prolonged	O
survival	O
of	O
34	O
months	O
.	O

A	O
bleomycin	O
,	O
etoposide	B:C0015133
,	O
and	O
cisplatin	O
treatment	O
protocol	I:C0040808
targeting	O
germ	O
cell	I:C4021985
neoplasia	I:C4021985
lead	O
to	O
disease	O
remission	I:C0544452
and	O
prolonged	O
survival	O
of	O
34	O
months	O
.	O

A	O
bleomycin	O
,	O
etoposide	O
,	O
and	O
cisplatin	B:C0008838
treatment	O
protocol	I:C0040808
targeting	O
germ	O
cell	I:C4021985
neoplasia	I:C4021985
lead	O
to	O
disease	O
remission	I:C0544452
and	O
prolonged	O
survival	O
of	O
34	O
months	O
.	O

A	O
bleomycin	O
,	O
etoposide	O
,	O
and	O
cisplatin	O
treatment	B:C0040808
protocol	I:C0040808
targeting	O
germ	O
cell	I:C4021985
neoplasia	I:C4021985
lead	O
to	O
disease	O
remission	I:C0544452
and	O
prolonged	O
survival	O
of	O
34	O
months	O
.	O

A	O
bleomycin	O
,	O
etoposide	O
,	O
and	O
cisplatin	O
treatment	O
protocol	I:C0040808
targeting	O
germ	B:C4021985
cell	I:C4021985
neoplasia	I:C4021985
lead	O
to	O
disease	O
remission	I:C0544452
and	O
prolonged	O
survival	O
of	O
34	O
months	O
.	O

A	O
bleomycin	O
,	O
etoposide	O
,	O
and	O
cisplatin	O
treatment	O
protocol	I:C0040808
targeting	O
germ	O
cell	I:C4021985
neoplasia	I:C4021985
lead	O
to	O
disease	B:C0544452
remission	I:C0544452
and	O
prolonged	O
survival	O
of	O
34	O
months	O
.	O

Comprehensive	O
immunohistochemical	O
and	O
genetic	B:C0393006
testing	I:C0393006
is	O
essential	O
to	O
identify	O
uncommon	O
cancers	I:C4054123
possibly	O
related	O
to	O
Lynch	O
syndrome	I:C2931459
.	O

Comprehensive	O
immunohistochemical	O
and	O
genetic	O
testing	I:C0393006
is	O
essential	O
to	O
identify	O
uncommon	B:C4054123
cancers	I:C4054123
possibly	O
related	O
to	O
Lynch	O
syndrome	I:C2931459
.	O

Comprehensive	O
immunohistochemical	O
and	O
genetic	O
testing	I:C0393006
is	O
essential	O
to	O
identify	O
uncommon	O
cancers	I:C4054123
possibly	O
related	O
to	O
Lynch	B:C2931459
syndrome	I:C2931459
.	O

For	O
rare	B:C4054123
tumors	I:C4054123
,	O
personalized	O
therapeutic	O
approaches	I:C0087111
should	O
take	O
both	O
molecular	O
and	O
morphological	O
information	O
into	O
account	O
.	O

For	O
rare	O
tumors	I:C4054123
,	O
personalized	O
therapeutic	B:C0087111
approaches	I:C0087111
should	O
take	O
both	O
molecular	O
and	O
morphological	O
information	O
into	O
account	O
.	O

